United States· US:65219-584_90995548-9bf5-42ce-a93f-26b51a58044d
TYENNE
A tocilizumab product containing tocilizumab-aazg, registered in United States by Fresenius Kabi USA, LLC. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Tocilizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC L04AC07 (tocilizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Tocilizumab · ATC L04AC07
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tocilizumab costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tocilizumab · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$29.63
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Tocilizumab-aazg
- Manufacturer
- Fresenius Kabi USA, LLC
- Country
- United States (US)
- ATC code
- L04AC07
- ATC class
- Tocilizumab
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1165219584011 SYRINGE, GLASS in 1 CARTON (65219-584-01) / .9 mL in 1 SYRINGE, GLASS
Regulatory notes
Interactions
263 interactions on record for tocilizumab.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tocilizumab · interactions on record
263 records
- 38 severe
- 218 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tocilizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAVTOZMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumAvtozma 162 mgCelltrion Healthcare Hungary
- SwitzerlandActemra
- United KingdomAvtozma 162mg/0.9ml solution for injection pre-filled pensCelltrion Healthcare UK Ltd
- SpainAVTOZMA 162 MG SOLUCION INYECTABLE EN JERINGA PRECARGADACelltrion Healthcare Hungary Kft.
- IcelandAvtozmaCelltrion Healthcare Hungary Kft.
- FinlandAvtozmaCelltrion Healthcare Hungary Kft.
- IrelandAvtozma 162 mg solution for injection in pre-filled penCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tofidence
- Iceland · Avtozma, Roactemra
- Liechtenstein · Avtozma, Roactemra
- Norway · Avtozma, Roactemra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e70716c3-a5ef-42cb-8a48-38a92f526881 GET /v1/drugs/e70716c3-a5ef-42cb-8a48-38a92f526881?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "I031V2H011",
"rxcui": "612865",
"inchikey": null,
"display_name": "TOCILIZUMAB",
"substance_type": "protein",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 3
},
"spl_meta": {
"ad76441d-da59-47df-8d9d-2243005180f0": {
"match": "brand_token",
"title": "TYENNE (TOCILIZUMAB-AAZG) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]",
"spl_version": "4",
"published_date": "2025-12-04"
}
},
"productid": "65219-584_90995548-9bf5-42ce-a93f-26b51a58044d",
"productndc": "65219-584",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "TOCILIZUMAB",
"proprietary_name": "TYENNE",
"active_ingred_unit": "mg/.9mL",
"application_number": "BLA761275",
"marketing_category": "BLA",
"nonproprietary_name": "Tocilizumab-aazg",
"start_marketing_date": "20240701",
"active_numerator_strength": "162"
}See everything about tocilizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.